Tegoprazan

看中罗欣健康科技发展(北京)有限公司(简称“北京健康”)的是创新药商业化及推广经验，罗欣药业向其增资1.2亿元。 12月24日晚罗欣药业公告，拟增加子公司北京健康注册资本1.2亿元，本次增资完成后，公司对北京健康持股比例将由71.16%升至80.95%。 资料显示，北京健康经营范围包含销售食品；销售药品；提供互联网药品、医疗器械信息服务等，注册资本为2.34亿元。今年前三季度，该公司营收3.47亿元，净利润亏损1.58亿元；截至9月30日，资产总额为1.05亿元，净资产为-3.99亿元。 本次交易将有利于满足北京健康业务发展的资金需求，使得北京健康能够利用公司的产品资源优势，积极推进产品商业化运营，加强建设创新药推广能力，保障北京健康的业务发展需要。 同时，罗欣药业也表示，公司对北京健康增资，是为了进一步增强对北京健康的控制，把握战略机遇，利用公司的产品资源优势，积极推进产品商业化运营，加强建设创新药推广能力，促进公司产生良好的协同效应，符合公司未来发展方向和战略。 据悉，罗欣药业聚焦于消化、呼吸、抗肿瘤等优势领域，并在创新药、仿制药两方面发力，上市了150余个品种，300多个品规的产品。 其中，在创新药方面，罗欣药业聚焦消化领域，2022年公司头个1类新药替戈拉生片(商品名：泰欣赞®)获批上市，该产品为钾离子竞争性酸阻滞剂(Potassium-Competitive Acid Blockers，P-CAB)，适用于治疗反流性食管炎、十二指肠溃疡及与适当的抗生素联用以根除幽门螺杆菌共计三项适应症，前两项适应症已被纳入2024版国家医保目录。 在仿制药方面，罗欣药业以呼吸领域产品为例，公司以儿童患者临床需求出发历时多年研发推出的2.4类新药为头个国内上市的盐酸氨溴索喷雾剂(商品名：佩宁®)，该产品适用于2-6岁儿童的痰液粘稠及排痰困难。 但是从业绩上来看，近年来，罗欣药业的业绩并不理想。数据显示，自2022年起，罗欣药业开始陷入亏损。2022年的净亏损高达12.25亿元，同比上年下滑401.63%，实现营收35.88亿元，同比上年下滑44.62%。到了2023年，罗欣药业净利润亏损面积有所缩小，但净利润仍为-6.61亿元，营收进一步下滑为23.64亿元。 进入2024年，罗欣药业仍未扭转亏损局面，前三季度报告显示，净利润亏损为2.65亿元，实现营业收入18.81亿元，同比增长2.98%。照此计算，不到三年时间，罗欣药业累计亏损约21.51亿元。 据悉，面临业绩的亏损，罗欣药业还曾通过出售子公司盘活资产。如今年11月，罗欣药业曾公告，拟通过公开挂牌方式出售其全资子公司乐康制药100%股权，拟挂牌价格1.9亿元。罗欣药业表示，此次交易有利于公司盘活资产，优化公司资源配置，增强公司的盈利能力和抗风险能力。 而此次对资不抵债的北京健康进行增资，罗欣药业看中的是其创新药商业化及推广经验。罗欣药业表示，北京健康的主营业务为药品销售，拥有丰富的创新药商业化及推广经验。 来源：制药网 商务合作 130 6172 3098 zakk.cui@siqibest.com 点击 阅读原文 了解更多

December 12, 2024 HK inno.N’s K-CAB, new drug for Gastroesophageal Reflux Disease (GERD) treatment, launched in 6 additional Latin American countries Product launch in 6 countries including ▲Dominican Republic ▲Nicaragua ▲Honduras … K-CAB now available in 15 countries worldwide Ranked 3rd in the Mexican market within a year of its launch… market share of 10% in sight HK inno.N announced on 12 December that K-CAB (tegoprazan) for gastroesophageal reflux disease (GERD), was launched in six additional Central and South American countries. The six countries in the region with the recent product launch of K-CAB are ▲Dominican Republic ▲Nicaragua ▲Honduras ▲Guatemala ▲El Salvador ▲Colombia. K-CAB already obtained the marketing authorization under the local product name "Ki-CAB" in September. K-CAB’s bold strides of market expansion in Latin America include 18 countries, either in the form of exporting finished products or technology export. Following its launch in Mexico and Peru last year, the product was released in Chile in the second half of this year and is now launched in 6 more countries in the continent, establishing its market presence across 9 countries of Latin America at a remarkable pace. Carnot, HK inno.N's partner that signed a contract with HK inno.N for exporting and distribution of K-CAB to 17 Latin American countries excluding Brazil, has been active in its marketing campaigns to lead the market growth of K-CAB (the local product name "Ki-CAB.") in the Central and South American markets. As part of the partnership, HK inno.N and Carnot have jointly hosted an academic conference for medical specialists in South Korea and Latin America since the last year. In October this year, a symposium was held in Bogota, Colombia, in celebration of K-CAB’s launch in the country. A number of eminent gastroenterologists from the Americas attended the event, gave presentations, and had lively discussions on the clinical benefits of K-CAB and the areas where it can be used as a new treatment option. Dr David A. Peura, an emeritus professor in gastroenterology at University of Verginia, Charlottesville, the U.S., presented in his lecture at the Colombia symposium, “K-CAB should be considered as an option for all cases of Helicobacter pylori eradication therapy requiring acid suppression.” Dr. Marcelo Vela of the Mayo Clinic in the U.S. reported, “K-CAB has a faster onset of action in suppressing gastric acid than other potassium competitive acid blockers (P-CAB) and has greater benefits than proton pump inhibitors (PPIs) in the treatment of GERD in patients with moderate to severe reflux esophagitis (LA grade B/C/D).” An official from Carnot stated, "K-CAB landed on its position as the top 3 peptic ulcer medicines in Mexico within a year from its launch and is close to achieving the 10% market share," and added, " the rapid pace of growth of K-CAB has had a positive impact on the Latin American market, and medical specialists in other countries in the continent where K-CAM has not been introduced yet have expressed great interest and expectations. HK inno.N’s CEO Dalwon Kwak commented, “K-CAB has quickly gained prominence in the Central and South American market, and our efforts to promote the value of the Korean new drug in the global peptic ulcer market will continue to expand, beyond Latin America.” K-CAB, the 30th new drug of South Korea, is a P-CAB class new drug for GERD treatment. It is characterized by rapid onset of action within one hour after administration and proven efficacy and safety even with long-term use for up to six months. Recently, the Mexican Association of Gastroenterology (the Asociación Mexicana de Gastroenterología) published a guideline recommending P-CAB class drugs from the early stage in the treatment course of GERD, which is expected to further increase the influence of K-CAB in the market of peptic ulcer medications in Central and South America. Following its first launch in South Korea, K-CAB succeeded in the market entry to a total of 46 countries worldwide, including the U.S. and China. The product has been officially released in 15 countries to date, demonstrating its growing global market presence. K-CAB recorded a total outpatient prescription sales of KRW 177.7 billion from January to November for this year alone in South Korea. The product has been the steady No. 1 market leader in peptic ulcer medications for four consecutive years since its launch. [The End] [Reference information] ■ P-CAB: Potassium Competitive Acid Blocker ■ PPI: Proton Pump Inhibitor ■ The Mexican Association of Gastroenterology: Asociación Mexicana de Gastroenterología ■ Overview of K-CAB’s market presence worldwide (46 countries in total): - South Korea, China, Mongolia, India, South Africa, the U.S, Canada - 6 Southeast Asian countries: Indonesia, Thailand, the Philippines, Vietnam, Singapore, Malaysia - 5 Eastern European countries: Russia, Kazakhstan, Uzbekistan, Ukraine, Belarus - 10 Middle Eastern/North African countries - 18 Central and South American countries (see below) ■ K-CAB’s market entry to Central and South America includes the following 18 countries: Brazil, Mexico, Argentina, Colombia, Peru, Chile, Ecuador, Uruguay, Paraguay, Bolivia, Venezuela, Dominican Republic, Guatemala, Honduras, Nicaragua, Costa Rica, Panama, and El Salvador (Of these, Carnot is an exporter for 17 countries, which excludes Brazil). ■ Overview of K-CAB’s market presence in Central and South America - Technology transfer (1 country): Brazil - Product release (9 countries): Mexico, Peru, Colombia, Chile, Dominican Republic, Nicaragua, Honduras, Guatemala, and El Salvador.